Engineered immune cells take on kidney cancer in early trial
NCT ID NCT03354390
First seen May 01, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This early-phase study tests a new gene therapy for people with advanced clear cell kidney cancer. Doctors take a patient's own white blood cells, modify them in the lab to better recognize and attack cancer cells, and then return them to the patient. The main goals are to check safety and see if the treatment can shrink tumors. About 17 adults with a specific genetic type (HLA-A 11:01) will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.